Uwe Reinhardt - Tekla Life Independent Trustee
| HQL Stock | USD 12.79 0.03 0.23% |
Executive
Dr. Uwe E. Reinhardt, Ph.D. is Independent Trustee of HQ Life Sciences Investors. Dr. Reinhardt is the James Madison Professor of Political Economy at Princeton University, teaching economics and public affairs since 1968, and was a member of the Institute of Medicine of the National Academy of Sciences since 1978. He serves on the Audit Committee of each Fund. Dr. Reinhardt is recognized as one of the nation leading authorities on health care economics, a prominent scholar in health care economics and a frequent speaker and author on subjects ranging from the war in Iraq to the future of Medicare. Dr. Reinhardt provides each Fund with valuable insights in healthcare economics and reform. He is a past president of the Association of Health Services Research. From 1986 to 1995 he served as a commissioner on the Physician Payment Review Committee, established in 1986 by Congress to advise it on issues related to the payment of physicians. He is a senior associate of the Judge Institute for Management of Cambridge University, UK, and a trustee of Duke University and the Duke University Health System. Dr. Reinhardt is or was a member of numerous editorial boards, among them the Journal of Health Economics, the Milbank Memorial Quarterly, Health Affairs, the New England Journal of Medicine, and the Journal of the American Medical Association since 1992.
| Age | 79 |
| Tenure | 32 years |
| Professional Marks | Ph.D |
| Address | 1900 Market Street, Philadelphia, PA, United States, 19103 |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hql.html |
Tekla Life Management Efficiency
Return On Capital Employed is expected to rise to 0.05 this year, although the value of Return On Tangible Assets will most likely fall to 0.04. At this time, Tekla Life's Total Current Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0.06 this year, although the value of Total Assets will most likely fall to about 335.6 M. Tekla Life's management efficiency ratios could be used to measure how well Tekla Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | EXECUTIVE Age | ||
| Robert Neve | Four Leaf Acquisition | 64 | |
| Jinwei Kou | Four Leaf Acquisition | 42 | |
Management Performance
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 |
Tekla Life Sciences Leadership Team
Elected by the shareholders, the Tekla Life's board of directors comprises two types of representatives: Tekla Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Life's management team and ensure that shareholders' interests are well served. Tekla Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Bonney, Independent Trustee | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Dr MS, President Officer | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, Principal Executive Officer and President Trustee and Member of Valuation Committee | ||
| Rakesh Jain, Independent Trustee | ||
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
| Peter Branner, Chief Officer | ||
| Uwe Reinhardt, Independent Trustee |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | 1.56 % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 344.58 M | ||||
| Shares Outstanding | 26.79 M | ||||
| Shares Owned By Institutions | 35.53 % | ||||
| Number Of Shares Shorted | 21.32 K | ||||
| Price To Earning | 2.84 X | ||||
| Price To Book | 0.87 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tekla Life in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tekla Life's short interest history, or implied volatility extrapolated from Tekla Life options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Tekla Stock analysis
When running Tekla Life's price analysis, check to measure Tekla Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tekla Life is operating at the current time. Most of Tekla Life's value examination focuses on studying past and present price action to predict the probability of Tekla Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tekla Life's price. Additionally, you may evaluate how the addition of Tekla Life to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Tekla Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Dividend Share 1.3 | Earnings Share 0.79 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.344 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.